Immuneering (IMRX) News
NASDAQ: IMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.38-0.07 (-2.03%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMRX news summary
We found 13 recent headlines mentioning Immuneering (IMRX): 3 in the past week and 13 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, IMRX is down 2.03% at $3.38. The most recent story, "Immuneering Releases Data Validating Atebimetinib As MAPK Backbone In Pancreatic & Thyroid Cancer", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Immuneering headlines
- Immuneering Releases Data Validating Atebimetinib As MAPK Backbone In Pancreatic & Thyroid Cancer(RTTNews) - Immuneering Corporation (IMRX), a late-stage oncology company, on Wednesday released data supporting lead drug candidate Atebimetinib as a potential therapeutic for pancreatic and thyroid…NasdaqIMRX, BF.A
- Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic CancerImmuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic CancerGlobeNewswire
- Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid CancerImmuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid CancerGlobeNewswire
- Astellas, Immuneering Enter Pancreatic Cancer Trial Collaboration(RTTNews) - Japanese drugmaker Astellas Pharma Inc. (ALPMY) announced on Thursday that it has entered into a clinical trial collaboration and supply agreement with Immuneering Corp. (IMRX) to…Nasdaq
- Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid CancerImmuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid CancerGlobeNewswire
- Immuneering Corporation Appoints Grant C. Bogle to Board of Directors on November 9, 2026Immuneering Corporation announced that on November 9, 2026, its Board of Directors appointed Grant C. Bogle, MBA, to serve as a member of the Board as a Class III Director. There was no arrangement…Nasdaq
- Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of DirectorsImmuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of DirectorsGlobeNewswire
- Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026- Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped -GlobeNewswire
- Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceImmuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswire
- Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR SymposiumImmuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR SymposiumGlobeNewswire
- Immuneering Corporation Reports Third Quarter 2026 Financial Results and Provides Business UpdatesImmuneering Corporation reported its financial results for the third quarter ended September 30, 2026, and provided clinical updates. The company announced that follow-up in its Phase 2 trial of…Nasdaq
- Immuneering Reports Third Quarter 2026 Financial Results and Provides Business UpdatesImmuneering Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026GlobeNewswire